News

If approved, Latisse would be the first and only FDA-approved pharmaceutical to enhance eyelash prominence, the company said. In addition to its unanimous recommendation for approval of Latisse,

According to the company, the patent broadly relates to the administration of compositions containing bacteriophages to individuals colonized with pathogenic bacteria in order to prevent the development of

Pursuant to the terms of the collaboration, Galapagos’s service division, BioFocus DPI, will develop a cell-based assay for Dart Neuroscience’s (DNS’s) drug discovery programs for brain disorders and

Under the extension to the licensing agreement, Palatin will receive an upfront payment of $1.6 million and AstraZeneca has been granted licenses to additional compounds and patents. Additionally,

Under the terms of the agreement, Roche Applied Science will market cell-systems, based on the technology of Axiogenesis Cor.At being customized for the xCELLigence platform. The Roche xCELLigence

The Phase II randomized, double-blind, multi-center trial will evaluate the safety, tolerability and efficacy of an intravenous bolus of PRT060128 followed by one of three doses (50mg, 100mg,

Primary objectives for the dose escalation study include determining the maximum tolerated dose and dose limiting toxicity of ENMD-2076 when administered orally once a day in patients with

Under the terms of the agreement, Galen will pay Stellar an upfront milestone payment plus a specified transfer price in exchange for the rights to an exclusive license

This clearance positions the company closer to its goal of commercializing its technology and increasing shareholder value, said Manhattan Scientifics. This patented new form of titanium metal originally